OSI Systems posts record Q2 revenue and lifts full-year EPS guidance, navigating softness in security bookings and healthcare challenges with optimism for a stronger second half.
In a volatile market, certain low-priced Asian stocks are drawing attention not just for their valuation, but for underlying financial strength. We examine three such companies—from healthcare in New Zealand to property services in Greater China—that defy the typical 'penny stock' stereotype with solid fundamentals.
AppFolio Inc. reported a 22% year-over-year revenue surge in its fourth quarter, driven by AI innovation and premium product adoption, while navigating industry-wide cost pressures. The company also issued optimistic guidance for 2026.
Amid corporate restructuring fears, a professional with a substantial nest egg but no home equity grapples with the daunting math of early retirement, soaring healthcare costs, and an uncertain housing market.
Cardinal Health (CAH) stock has drawn renewed investor interest following robust financial results, with revenue topping $234 billion and net income near $1.6 billion. The healthcare distributor's shares have rallied over 66% in the past year, though its premium valuation compared to peers is sparking debate among analysts.
Once a symbol of tech retrenchment, San Francisco's Showplace Square is undergoing a profound transformation. Major leases by AI firms Together AI and Physical Intelligence, coupled with Vanderbilt University's planned campus, are redefining the neighborhood as a nexus for technology, education, and innovation, offering a significant boost to the city's office recovery narrative.
Powersports giant Polaris unveils an industry-first active suspension system in its flagship RZR, alongside approving its 31st consecutive annual dividend increase, signaling a dual focus on innovation and shareholder returns amid portfolio restructuring.
In a strategic reshuffle following the exit of its product chief, Netflix has merged its product and technology divisions under veteran executive Elizabeth Stone, signaling a tighter integration of engineering and user experience.
Craig-Hallum and Northland Securities have both lowered price targets for MiMedx Group (MDXG), citing near-term uncertainty following new CMS billing guidance for skin substitute products, though both firms maintain positive long-term ratings.
A significant reset in analyst price targets for iRhythm Holdings (IRTC) is prompting investors to reassess the cardiac monitoring firm's risk-reward profile. This shift reflects evolving views on reimbursement headwinds, competitive pressures, and long-term growth catalysts in the digital health sector.
Abbott Laboratories moves to acquire cancer-testing leader Exact Sciences in a landmark deal, signaling a strategic shift toward high-growth diagnostics while simultaneously restructuring its challenged Nutrition business.
IDEAYA Biosciences shares have retreated from recent highs, sparking debate among investors. While a discounted cash flow model suggests deep undervaluation, price-to-sales metrics paint a contrasting picture of a premium stock. We examine the numbers behind the volatility and what it signals for the precision oncology company's future.
While Wall Street chases the latest weight-loss drug headlines, Novo Nordisk's recent launch of an oral GLP-1 therapy and its entrenched insulin business present a compelling value proposition for long-term investors.
French pharmaceutical giant Sanofi has discontinued development of its experimental mRNA flu vaccine, citing a strategic reprioritization. The decision comes as influenza activity remains high across much of the United States, with significant hospitalizations and deaths reported this season.
While 3M shares have significantly underperformed the broader market and its industrial peers over the past year, Wall Street maintains a cautiously optimistic stance, betting on the diversified giant's long-term recovery and earnings resilience.
Spanish healthtech startup Biorce has closed a substantial Series A round, backed by prominent venture capital and angel investors, to scale its AI-driven clinical trial solution, Aika, internationally amid a tightening regulatory landscape.
As major indices climb, investors are sifting through economic crosscurrents to find resilient tech innovators. We examine three companies—Veracyte, monday.com, and Zeta Global—whose strategic moves and financial momentum position them for potential growth.
Adobe and Cognizant are expanding their strategic partnership to help major corporations integrate generative AI into content creation and customer experience workflows. The move targets regulated, high-growth industries grappling with soaring demand for personalized content, positioning Adobe's tools as enterprise-ready solutions amid investor scrutiny over its stock performance.
Amazon will discontinue its Amazon One palm-scanning payment and entry technology at retail locations in 2026, marking a retreat from one of its most ambitious physical commerce experiments.
IBM intensifies its focus on the enterprise AI market with the launch of its governed deployment platform, a strategic collaboration with e& for regulated sectors, and the appointment of PepsiCo's Ramon Laguarta to its board of directors.
